ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 19 of 13174 for:    "Diabetes Mellitus"

An Exploratory Study to Evaluate the Effects of Trelagliptin and Alogliptin by CGM on Glucose Variability for One Week With Type 2 Diabetes Mellitus (TRACK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02771093
Recruitment Status : Completed
First Posted : May 12, 2016
Last Update Posted : May 10, 2017
Sponsor:
Information provided by (Responsible Party):
Takeda

Brief Summary:
This is a multi-center, randomized, open-label, parallel-group comparative, exploratory study to evaluate the effect of trelagliptin administered at a dose of 100 mg once weekly or alogliptin administered at a dose of 25 mg once daily for 4 weeks on glycemic variation in patients with type 2 diabetes mellitus using continuous glucose monitoring (CGM).

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: Trelagliptin Drug: Alogliptin Phase 4

Detailed Description:
The purpose of this study is to evaluate the effect of trelagliptin administered orally at a dose of 100 mg once weekly or alogliptin administered orally at a dose of 25 mg once daily for 4 weeks on glycemic variation in an exploratory manner and as preliminary to examine the influence of the once-weekly administration and blood glucose fluctuations due to the difference in the daily administration in participants with type 2 diabetes mellitus.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Exploratory Study to Evaluate the Effects of Trelagliptin and Alogliptin by CGM on Glucose Variability for One Week With Type 2 Diabetes Mellitus
Actual Study Start Date : June 1, 2016
Actual Primary Completion Date : April 27, 2017
Actual Study Completion Date : April 27, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Alogliptin

Arm Intervention/treatment
Experimental: Trelagliptin 100 mg group
Trelagliptin 100 mg once weekly taken orally before breakfast
Drug: Trelagliptin
Trelagliptin 100 mg tablet
Other Name: Zafatek Tablets

Experimental: Alogliptin 25 mg group
Alogliptin 25 mg once daily taken orally before breakfast
Drug: Alogliptin
Alogliptin 25 mg tablet
Other Name: Nesina Tablets




Primary Outcome Measures :
  1. Changes from Baseline in the standard deviation (SD) of 24-hour blood glucose values (mg/dL) [ Time Frame: Up to 31 days ]
    Changes in the standard deviation (SD) of 24-hour blood glucose values (mg/dL) for each 7-day period between Week 3 and Week 4 (between Day 22 and Day 28) of the treatment period, calculated from the value at the start of the observation period


Secondary Outcome Measures :
  1. Change from Baseline in Area Under the Curve over time (AUC) for blood glucose when specific blood glucose levels are observed during the 3 hour time period after breakfast, lunch and evening meal [ Time Frame: Up to 31 days ]
    The specific blood glucose levels at which AUC will be measured are 110, 140, 160, or 180 mg/dL

  2. Change from Baseline in AUC for blood glucose during periods when blood glucose levels reach 140, 160, or 180 mg/dL (hyperglycemia) [ Time Frame: Up to 31 days ]
  3. Change from Baseline in Time during periods when blood glucose levels reach 140, 160, or 180 mg/dL (hyperglycemia) [ Time Frame: Up to 31 days ]
  4. Change from Baseline in AUC for blood glucose during periods when blood glucose levels is less than 70 mg/dL (hypoglycemia) [ Time Frame: Up to 31 days ]
  5. Change from Baseline in peak postprandial glucose levels during the 3 hour time period after breakfast, lunch and evening meal [ Time Frame: Up to 31 days ]
  6. Change from Baseline in maximum variation of blood glucose levels between before and after breakfast, lunch, and evening meal [ Time Frame: Up to 31 days ]
  7. Change from Baseline in Mean Amplitude Glycemic Excursions (MAGE) [ Time Frame: Up to 31 days ]
  8. Change from baseline in mean 24-hour blood glucose levels [ Time Frame: Up to 31 days ]
  9. Change from baseline in mean daytimeblood glucose levels [ Time Frame: Up to 31 days ]
  10. Change from baseline in mean nocturnal blood glucose levels [ Time Frame: Up to 31 days ]
  11. Change from baseline in AUC for blood glucose [ Time Frame: Up to 31 days ]
  12. Change from baseline in AUC for blood glucose during periods when blood glucose levels reach 110 mg/dL [ Time Frame: Up to 31 days ]
  13. SD of 24-hour blood glucose values [ Time Frame: Up to 31 days ]
  14. Changes in the SD of daytime blood glucose values [ Time Frame: Up to 31 days ]
  15. Changes in the SD of nocturnal blood glucose values [ Time Frame: Up to 31 days ]
  16. Number of Participants Reporting One or More Treatment-emergent Adverse Events [ Time Frame: Up to 31 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants who, in the opinion of the principal investigator or the investigator, are capable of understanding the content of the clinical research and complying with the research protocol requirements.
  2. Participants who are able to sign and date the informed consent form and information sheet prior to the start of study procedures
  3. Participants diagnosed with type 2 diabetes mellitus
  4. Participants with an HbA1c (NGSP value) value ≥ 6.5% and < 8.5% at the start of the observation period (Day -2)
  5. Participants who experience a ≤ ±1.0% change in HbA1c (NGSP value) at the start of the observation period (Day -2) as compared with an HbA1c value obtained during the preceding 6 weeks
  6. Participants receiving stable dietetic therapy and exercise therapy (if performed) for ≥ 4 weeks before the start of the observation period
  7. Participants, who in the opinion of the principal investigator or the investigator, does not have to change (including discontinuation or interruption) HMG-CoA reductase inhibitors or add new HMG-CoA reductase inhibitors during treatment period.
  8. Men or women aged 20 years or older at the time of informed consent.

Exclusion Criteria:

  1. Participants who received anti-diabetic medications within 4 weeks prior to the start of the observation period
  2. Participants who have changed (including discontinuation or interruption) HMG-CoA reductase inhibitors or received new HMG-CoA reductase inhibitors ≤ 4 weeks before the start of the observation period.
  3. Participants with clinically evident hepatic dysfunction (e.g., AST or ALT ≥ 2.5-fold the upper limit of normal at the start of the observation period [Day -2])
  4. Participants with moderate renal dysfunction, severe renal dysfunction or renal failure (e.g., creatinine clearance < 50 mL/min or serum creatinine > 1.4 mg/dL in men or > 1.2 mg/dL in women [equivalent to the creatinine clearance for persons aged 60 years with a body weight of 65 kg] at the start of the observation period [Day -2])
  5. Participants with severe heart disease, cerebrovascular disorder, or severe pancreatic, hematologic or other diseases
  6. Participants with a history of gastric or small intestinal resection
  7. Participants with proliferative diabetic retinopathy
  8. Participants warranting insulin therapy for glycemic control (e.g., participants with severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, perioperative participants, or serious trauma)
  9. Participants with a history of hypersensitivity or allergy to DPP-4 inhibitors
  10. Participants who experience an allergic reaction to metal during CGM at the start of the observation period (Day -2)
  11. Participants with any malignant tumors
  12. Habitual drinkers whose average daily alcohol consumption is > 100 mL
  13. Participants who have any contraindications for the study drug or are taking any contraindicated concomitant drugs listed in the package insert
  14. Participants anticipated to require any prohibited concomitant medications during the study period
  15. Participants who are day and night lifestyle reversal
  16. Participants participating in any other clinical studies at the time of informed consent for this study
  17. Pregnant women, nursing mothers, women who are possible pregnant, or women who plan to become pregnant
  18. Other participants who are considered inappropriate for participation in this study in the opinion of the principal investigator or investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02771093


Locations
Japan
Naka-city, Ibaragi, Japan
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director Takeda

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT02771093     History of Changes
Other Study ID Numbers: Trelagliptin-4001
U1111-1182-4062 ( Other Identifier: UTN )
First Posted: May 12, 2016    Key Record Dates
Last Update Posted: May 10, 2017
Last Verified: May 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Takeda:
Type 2, Diabetes, Diabetes Mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Alogliptin
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action